 |
Indication & Dosage |
| |
| |
| Intravenous |
| SOFT TISSUE SARCOMA |
| Adult:
250 mg/m2 BSA daily for 5 days repeated every 3 wk. Usually given with doxorubicin. |
| |
| Intravenous |
| METASTATIC MALIGNANT MELANOMA |
| Adult:
2-4.5 mg/kg daily for 10 days, repeat at 4-wk intervals or 200-250 mg/m2 BSA daily for 5 days, repeat at 3-wk intervals or 850 mg/m2 BSA by infusion, repeat at 3-wk intervals. |
| |
| Intravenous |
| HODGKIN'S DISEASE |
| Adult:
150 mg/m2 BSA daily for 5 days, repeat every 4 wk or 375 mg/m2 BSA every 15 days in combination with other agents. |
|
| |
|
| Precautions |
Hepatic or renal impairment. Pregnancy, lactation. |
| |
|
Potentially Life-threatening
Adverse Drug Reactions |
Leucopenia, thrombocytopenia, anorexia, nausea, diarrhoea, vomiting; flu-like syndrome, myalgia, malaise, facial flushing, paraesthesia, skin reactions, rashes; alopoecia, photosensitivity reactions. |
| |
|
| Adverse Drug Reactions |
Myelosuppression; hepatotoxicity, anaphylaxis. |
| |
|
| Interactions |
Impairs immune response to vaccines; possible infection after admin of live vaccines. Effect increased by CYP1A2 inhibitors e.g. amiodarone, ciprofloxacin, fluvoxamine, ketoconazole, lomefloxacin, ofloxacin and rofecoxib. Effect decreased by CYP1A2 inducers e.g. aminoglutethimide, carbamazepine, phenobarbital and rifampicin. |
| |
|
|
|
